leukemia |
Manually Genotype(Total Text Mining Genotypes:0) |
---|
(Waiting for update.) |
All Snps(Total Genotypes:104) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
rs1045642 | 23731124 | 5243 | ABCB1 | umls:C0023418 | BeFree | Association between the MDR1 gene variant C3435T and risk of leukaemia: a meta-analysis. | 0.054740296 | 2013 | ABCB1 | 7 | 87509329 | A | T,G |
rs1045642 | 22088099 | 5243 | ABCB1 | umls:C0023418 | BeFree | Variant genotypes of MDR1 C3435T increase the risk of leukemia: evidence from 10 case-control studies. | 0.054740296 | 2012 | ABCB1 | 7 | 87509329 | A | T,G |
rs10821936 | 24564228 | 84159 | ARID5B | umls:C0023418 | BeFree | The heterozygous genotype in ARID5B rs10821936 increased the risk for MLL-r leukemia in both white and non-white (OR 2.06, 95% CI: 1.12-3.79 and OR 2.36, 95% CI: 1.09-5.10, respectively). | 0.002638474 | 2014 | ARID5B | 10 | 61963818 | C | T |
rs10821936 | 24564228 | 4297 | KMT2A | umls:C0023418 | BeFree | The heterozygous genotype in ARID5B rs10821936 increased the risk for MLL-r leukemia in both white and non-white (OR 2.06, 95% CI: 1.12-3.79 and OR 2.36, 95% CI: 1.09-5.10, respectively). | 0.240150617 | 2014 | ARID5B | 10 | 61963818 | C | T |
rs11203366 | 17216583 | 23569 | PADI4 | umls:C0023418 | BeFree | The functional haplotype of peptidylarginine deiminase IV (S55G, A82V and A112G) associated with susceptibility to rheumatoid arthritis dominates apoptosis of acute T leukemia Jurkat cells. | 0.002995792 | 2007 | PADI4 | 1 | 17331039 | G | A |
rs11203367 | 17216583 | 23569 | PADI4 | umls:C0023418 | BeFree | The functional haplotype of peptidylarginine deiminase IV (S55G, A82V and A112G) associated with susceptibility to rheumatoid arthritis dominates apoptosis of acute T leukemia Jurkat cells. | 0.002995792 | 2007 | PADI4 | 1 | 17331121 | T | C |
rs113488022 | 24433452 | 673 | BRAF | umls:C0023418 | BeFree | Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias. | 0.002442977 | 2013 | BRAF | 7 | 140753336 | A | T,G,C |
rs113488022 | 22553924 | 673 | BRAF | umls:C0023418 | BeFree | We identified a novel breakpoint region at 14q32.13 that was rearranged together with IGH/14q32.33 in four cases of BRAF/V600E-negative leukemia/lymphoma with villous lymphocytes carrying either t(14;14)(q32.13;q32.33) (three patients) or del(14)(q32.13q32.33) (one patient). | 0.002442977 | 2012 | BRAF | 7 | 140753336 | A | T,G,C |
rs113488022 | 23349307 | 5594 | MAPK1 | umls:C0023418 | BeFree | We assessed phospho-ERK expression in 37 patients with hairy cell leukemia and 44 patients with neoplasms mimicking hairy cell leukemia (40 splenic marginal zone lymphoma, 2 hairy cell leukemia-variant and 2 splenic lymphoma/leukemia unclassifiable) using immunohistochemistry on routine biopsies and/or Western blotting on purified leukemic cells, and correlated the phospho-ERK status with the BRAF-V600E mutation status. | 0.007077352 | 2013 | BRAF | 7 | 140753336 | A | T,G,C |
rs113488022 | 24717435 | 673 | BRAF | umls:C0023418 | BeFree | The BRAF kinase is mutated, typically Val 600→Glu (V600E), to induce an active oncogenic state in a large fraction of melanomas, thyroid cancers, hairy cell leukaemias and, to a smaller extent, a wide spectrum of other cancers. | 0.002442977 | 2014 | BRAF | 7 | 140753336 | A | T,G,C |
rs113488022 | 25480661 | 673 | BRAF | umls:C0023418 | BeFree | BRAF-V600E is the key driver mutation in HCL and distinguishes it from other B-cell lymphomas, including HCL-like leukemias/lymphomas (HCL-variant and splenic marginal zone lymphoma). | 0.002442977 | 2015 | BRAF | 7 | 140753336 | A | T,G,C |
rs113488022 | 25120816 | 673 | BRAF | umls:C0023418 | BeFree | All 12 cases of HCL showed cytoplasmic BRAF V600E protein expression in leukemia cells by immunohistochemical study regardless of tumor burden, whereas all cases of HCL mimics including HCL-v, SMZL, and MZL were negative for BRAF V600E protein. | 0.002442977 | 2014 | BRAF | 7 | 140753336 | A | T,G,C |
rs113488022 | 23349307 | 2048 | EPHB2 | umls:C0023418 | BeFree | We assessed phospho-ERK expression in 37 patients with hairy cell leukemia and 44 patients with neoplasms mimicking hairy cell leukemia (40 splenic marginal zone lymphoma, 2 hairy cell leukemia-variant and 2 splenic lymphoma/leukemia unclassifiable) using immunohistochemistry on routine biopsies and/or Western blotting on purified leukemic cells, and correlated the phospho-ERK status with the BRAF-V600E mutation status. | 0.000814326 | 2013 | BRAF | 7 | 140753336 | A | T,G,C |
rs113488022 | 21663470 | 673 | BRAF | umls:C0023418 | BeFree | None of the 195 patients with other peripheral B-cell lymphomas or leukemias who were evaluated carried the BRAF V600E variant, including 38 patients with splenic marginal-zone lymphomas or unclassifiable splenic lymphomas or leukemias. | 0.002442977 | 2011 | BRAF | 7 | 140753336 | A | T,G,C |
rs11547328 | 12731669 | 1019 | CDK4 | umls:C0023418 | BeFree | Absence of R24C mutation of the CDK4 gene in leukemias and solid tumors. | 0.002442977 | 2003 | CDK4;MARCH9 | 12 | 57751648 | G | A |
rs121434592 | 19461960 | 207 | AKT1 | umls:C0023418 | BeFree | The E17K change results in constitutive AKT1 activation, induces leukaemia in mice, and accordingly, may be therapeutically exploited to target the PI3K pathway. | 0.011420422 | 2009 | AKT1 | 14 | 104780214 | C | T |
rs121434592 | 19461960 | 5291 | PIK3CB | umls:C0023418 | BeFree | The E17K change results in constitutive AKT1 activation, induces leukaemia in mice, and accordingly, may be therapeutically exploited to target the PI3K pathway. | 0.005428837 | 2009 | AKT1 | 14 | 104780214 | C | T |
rs121434592 | 19461960 | 5293 | PIK3CD | umls:C0023418 | BeFree | The E17K change results in constitutive AKT1 activation, induces leukaemia in mice, and accordingly, may be therapeutically exploited to target the PI3K pathway. | 0.005428837 | 2009 | AKT1 | 14 | 104780214 | C | T |
rs121434592 | 19461960 | 5290 | PIK3CA | umls:C0023418 | BeFree | The E17K change results in constitutive AKT1 activation, induces leukaemia in mice, and accordingly, may be therapeutically exploited to target the PI3K pathway. | 0.005971721 | 2009 | AKT1 | 14 | 104780214 | C | T |
rs121434592 | 19461960 | 5294 | PIK3CG | umls:C0023418 | BeFree | The E17K change results in constitutive AKT1 activation, induces leukaemia in mice, and accordingly, may be therapeutically exploited to target the PI3K pathway. | 0.00842463 | 2009 | AKT1 | 14 | 104780214 | C | T |
rs121434592 | 18665177 | 207 | AKT1 | umls:C0023418 | BeFree | The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias. | 0.011420422 | 2008 | AKT1 | 14 | 104780214 | C | T |
rs121434592 | 17921701 | 207 | AKT1 | umls:C0023418 | BeFree | They described a novel point mutation (E17K) in the pleckstrin homology domain (PHD) of the AKT1 gene in human breast, colorectal and ovarian cancers, and demonstrated that it induces leukemia in mice. | 0.011420422 | 2007 | AKT1 | 14 | 104780214 | C | T |
rs121434592 | 20440266 | 207 | AKT1 | umls:C0023418 | BeFree | Recently, the E17K mutation in the AKT1 has been associated with multiple human malignancies and leukemia in mice. | 0.011420422 | 2010 | AKT1 | 14 | 104780214 | C | T |
rs121434592 | 18504432 | 207 | AKT1 | umls:C0023418 | BeFree | The E17K change results in constitutive AKT1 activation and induces leukaemia in mice. | 0.011420422 | 2008 | AKT1 | 14 | 104780214 | C | T |
rs121912438 | 12967646 | 6647 | SOD1 | umls:C0023418 | BeFree | The effect of leukaemia inhibitory factor on SOD1 G93A murine amyotrophic lateral sclerosis. | 0.003267234 | 2003 | SOD1 | 21 | 31667299 | G | C |
rs121913227 | 24589925 | 4893 | NRAS | umls:C0023418 | BeFree | In a patient with a BRAF(V600K)-mutant melanoma responding to vemurafenib, we observed accelerated progression of a previously unrecognized NRAS-mutant leukemia. | 0.004885954 | 2015 | NA | NA | NA | NA | NA |
rs121913237 | 25316678 | 5609 | MAP2K7 | umls:C0023418 | BeFree | NRAS(G12V) maintained leukemia self-renewal through mTOR and MEK pathway activation, implicating these pathways as potential targets for cancer stem cell-specific therapies. | 0.001628651 | 2015 | NRAS | 1 | 114716126 | C | T,G,A |
rs121913237 | 25316678 | 4893 | NRAS | umls:C0023418 | BeFree | NRAS(G12V) maintained leukemia self-renewal through mTOR and MEK pathway activation, implicating these pathways as potential targets for cancer stem cell-specific therapies. | 0.004885954 | 2015 | NRAS | 1 | 114716126 | C | T,G,A |
rs121913237 | 21163920 | 4893 | NRAS | umls:C0023418 | BeFree | Injecting Mx1-Cre, LSL-Nras(G12D) mice with the MOL4070LTR retrovirus causes acute myeloid leukemia that faithfully recapitulates many aspects of human NRAS-associated leukemias, including cooperation with deregulated Evi1 expression. | 0.004885954 | 2011 | NRAS | 1 | 114716126 | C | T,G,A |
rs121913237 | 25316678 | 3689 | ITGB2 | umls:C0023418 | BeFree | In a multiplexed analysis of RAS-dependent signaling, Mac-1(Low) cells, which harbor leukemia stem cells, were preferentially sensitive to NRAS(G12V) withdrawal. | 0.000814326 | 2015 | NRAS | 1 | 114716126 | C | T,G,A |
rs121913237 | 25316678 | 4297 | KMT2A | umls:C0023418 | BeFree | Using computational approaches to explore our gene-expression data sets, we found that NRAS(G12V) enforced the leukemia self-renewal gene-expression signature and was required to maintain an MLL-AF9- and Myb-dependent leukemia self-renewal gene-expression program. | 0.240150617 | 2015 | NRAS | 1 | 114716126 | C | T,G,A |
rs121913237 | 25316678 | 3684 | ITGAM | umls:C0023418 | BeFree | In a multiplexed analysis of RAS-dependent signaling, Mac-1(Low) cells, which harbor leukemia stem cells, were preferentially sensitive to NRAS(G12V) withdrawal. | 0.001357209 | 2015 | NRAS | 1 | 114716126 | C | T,G,A |
rs121913448 | 15194504 | 25 | ABL1 | umls:C0023418 | BeFree | The resistance to the tyrosine kinase inhibitor imatinib in BCR/ABL-positive leukemias is mostly associated with mutations in the kinase domain of BCR/ABL, which include the most prevalent mutations E255K and T315I. | 0.089268157 | 2004 | ABL1 | 9 | 130862976 | G | A |
rs121913459 | 25686603 | 3791 | KDR | umls:C0023418 | BeFree | Here we combine comprehensive drug sensitivity and resistance profiling of patient cells ex vivo with structural analysis to establish the VEGFR tyrosine kinase inhibitor axitinib as a selective and effective inhibitor for T315I-mutant BCR-ABL1-driven leukaemia. | 0.004353001 | 2014 | ABL1 | 9 | 130872896 | C | T |
rs121913459 | 22985168 | 25 | ABL1 | umls:C0023418 | BeFree | Given the fact that all AKIs fail to inhibit BCR/ABL harboring the 'gatekeeper' mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia. | 0.089268157 | 2012 | ABL1 | 9 | 130872896 | C | T |
rs121913459 | 21926354 | 25 | ABL1 | umls:C0023418 | BeFree | Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. | 0.089268157 | 2011 | ABL1 | 9 | 130872896 | C | T |
rs121913459 | 25394714 | 25 | ABL1 | umls:C0023418 | BeFree | PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation. | 0.089268157 | 2014 | ABL1 | 9 | 130872896 | C | T |
rs121913459 | 25686603 | 613 | BCR | umls:C0023418 | BeFree | Here we combine comprehensive drug sensitivity and resistance profiling of patient cells ex vivo with structural analysis to establish the VEGFR tyrosine kinase inhibitor axitinib as a selective and effective inhibitor for T315I-mutant BCR-ABL1-driven leukaemia. | 0.051753097 | 2014 | ABL1 | 9 | 130872896 | C | T |
rs121913459 | 17671436 | 3320 | HSP90AA1 | umls:C0023418 | BeFree | We recently showed that inhibition of heat shock protein 90 (Hsp90) by a novel Hsp90 inhibitor, IPI- 504, causes BCR-ABL protein degradation, decreased numbers of leukemia stem cells, and prolonged survival of mice with CML induced by BCR-ABL-T315I. | 0.003800186 | 2007 | ABL1 | 9 | 130872896 | C | T |
rs121913459 | 22772060 | 25 | ABL1 | umls:C0023418 | BeFree | MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. | 0.089268157 | 2013 | ABL1 | 9 | 130872896 | C | T |
rs121913459 | 23190221 | 25 | ABL1 | umls:C0023418 | BeFree | Ponatinib was highly active in heavily pretreated patients with Ph-positive leukemias with resistance to tyrosine kinase inhibitors, including patients with the BCR-ABL T315I mutation, other mutations, or no mutations. | 0.089268157 | 2012 | ABL1 | 9 | 130872896 | C | T |
rs121913459 | 25686603 | 25 | ABL1 | umls:C0023418 | BeFree | Here we combine comprehensive drug sensitivity and resistance profiling of patient cells ex vivo with structural analysis to establish the VEGFR tyrosine kinase inhibitor axitinib as a selective and effective inhibitor for T315I-mutant BCR-ABL1-driven leukaemia. | 0.089268157 | 2014 | ABL1 | 9 | 130872896 | C | T |
rs121913459 | 15194504 | 25 | ABL1 | umls:C0023418 | BeFree | The resistance to the tyrosine kinase inhibitor imatinib in BCR/ABL-positive leukemias is mostly associated with mutations in the kinase domain of BCR/ABL, which include the most prevalent mutations E255K and T315I. | 0.089268157 | 2004 | ABL1 | 9 | 130872896 | C | T |
rs121913459 | 19366808 | 25 | ABL1 | umls:C0023418 | BeFree | Thus, sorafenib may provide an effective therapeutic measure to treat Ph+ leukemias, particularly those expressing the T315I mutant, which is totally resistant to imatinib and the second generation BCR/ABL inhibitors. | 0.089268157 | 2009 | ABL1 | 9 | 130872896 | C | T |
rs121913507 | 20553795 | 3815 | KIT | umls:C0023418 | BeFree | In most patients with systemic mastocytosis (SM), including aggressive SM (ASM) and mast cell (MC) leukemia (MCL), neoplastic cells express the oncogenic KIT mutation D816V, which confers resistance to imatinib. | 0.018673407 | 2010 | KIT | 4 | 54733155 | A | T |
rs121913507 | 18986703 | 3815 | KIT | umls:C0023418 | BeFree | Additionally, dasatinib induced apoptosis in mast cell and leukemia cell lines expressing KIT(D816V). | 0.018673407 | 2009 | KIT | 4 | 54733155 | A | T |
rs121913507 | 19804454 | 3815 | KIT | umls:C0023418 | BeFree | Two subclones of the HMC1 mast leukaemia cell line were used; both express an identical KIT allele-specific regulatory type mutation (V560G), but differ in that one also expresses an enzymatic site type mutation (D816V) that confers on them resistance to imatinib mesylate tyrosine kinase inhibitor. | 0.018673407 | 2010 | KIT | 4 | 54733155 | A | T |
rs121913514 | 22101339 | 862 | RUNX1T1 | umls:C0023418 | BeFree | Here we studied the effects of Bacillus intermedius RNase (binase) on murine myeloid progenitor cells FDC-P1; transduced FDC-P1 cells ectopically expressing mutated human KIT N822K oncogene and/or human AML1-ETO oncogene; and human leukemia Kasumi-1 cells expressing both of these oncogenes. | 0.035337101 | 2011 | KIT | 4 | 54733174 | T | A |
rs121913514 | 22101339 | 1218 | CMD1B | umls:C0023418 | BeFree | Here we studied the effects of Bacillus intermedius RNase (binase) on murine myeloid progenitor cells FDC-P1; transduced FDC-P1 cells ectopically expressing mutated human KIT N822K oncogene and/or human AML1-ETO oncogene; and human leukemia Kasumi-1 cells expressing both of these oncogenes. | 0.000271442 | 2011 | KIT | 4 | 54733174 | T | A |
rs121913514 | 22101339 | 861 | RUNX1 | umls:C0023418 | BeFree | Here we studied the effects of Bacillus intermedius RNase (binase) on murine myeloid progenitor cells FDC-P1; transduced FDC-P1 cells ectopically expressing mutated human KIT N822K oncogene and/or human AML1-ETO oncogene; and human leukemia Kasumi-1 cells expressing both of these oncogenes. | 0.115088437 | 2011 | KIT | 4 | 54733174 | T | A |
rs121913514 | 22101339 | 3815 | KIT | umls:C0023418 | BeFree | Here we studied the effects of Bacillus intermedius RNase (binase) on murine myeloid progenitor cells FDC-P1; transduced FDC-P1 cells ectopically expressing mutated human KIT N822K oncogene and/or human AML1-ETO oncogene; and human leukemia Kasumi-1 cells expressing both of these oncogenes. | 0.018673407 | 2011 | KIT | 4 | 54733174 | T | A |
rs121913514 | 22101339 | 3902 | LAG3 | umls:C0023418 | BeFree | Here we studied the effects of Bacillus intermedius RNase (binase) on murine myeloid progenitor cells FDC-P1; transduced FDC-P1 cells ectopically expressing mutated human KIT N822K oncogene and/or human AML1-ETO oncogene; and human leukemia Kasumi-1 cells expressing both of these oncogenes. | 0.000271442 | 2011 | KIT | 4 | 54733174 | T | A |
rs121913517 | 19804454 | 3815 | KIT | umls:C0023418 | BeFree | Two subclones of the HMC1 mast leukaemia cell line were used; both express an identical KIT allele-specific regulatory type mutation (V560G), but differ in that one also expresses an enzymatic site type mutation (D816V) that confers on them resistance to imatinib mesylate tyrosine kinase inhibitor. | 0.018673407 | 2010 | KIT | 4 | 54727444 | T | A,C,G |
rs121913521 | 19804454 | 3815 | KIT | umls:C0023418 | BeFree | Two subclones of the HMC1 mast leukaemia cell line were used; both express an identical KIT allele-specific regulatory type mutation (V560G), but differ in that one also expresses an enzymatic site type mutation (D816V) that confers on them resistance to imatinib mesylate tyrosine kinase inhibitor. | 0.018673407 | 2010 | KIT | 4 | 54727447 | T | A,G |
rs121913615 | 19194467 | 4352 | MPL | umls:C0023418 | BeFree | We conclude that MPL(W515L) occurs in a considerable proportion of acute megakaryoblastic leukaemias with myelofibrosis unrelated to PMF. | 0.005167327 | 2009 | MPL | 1 | 43349338 | G | T |
rs121918464 | 23884424 | 5781 | PTPN11 | umls:C0023418 | BeFree | Here, we report that induction of the Ptpn11(E76K/+) mutation, the most common and active Ptpn11 mutation found in leukemias and solid tumors, in primary mouse embryonic fibroblasts resulted in proliferative arrest and premature senescence. | 0.136697369 | 2014 | PTPN11 | 12 | 112450406 | G | A,C |
rs16754 | 21659357 | 7490 | WT1 | umls:C0023418 | BeFree | Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. | 0.142840843 | 2011 | WT1 | 11 | 32396399 | T | C |
rs17166050 | 24093751 | 10111 | RAD50 | umls:C0023418 | BeFree | The frequency of either the AA genotype or A allele of RAD50_rs17166050 were significantly different in controls compared to leukemia group (ALL+AML) (p<0.0019 and p<0.0019, respectively). | 0.000271442 | 2013 | RAD50 | 5 | 132579521 | G | A |
rs17433222 | 20438785 | 714 | C1QC | umls:C0023418 | GAD | [Polymorphisms in innate immunity genes and risk of childhood leukemia.] | 0.002367032 | 2010 | C1QB | 1 | 22652153 | G | A |
rs1800562 | 15775751 | 3077 | HFE | umls:C0023418 | BeFree | Given the population frequency of C282Y and the connection between iron and cancer, clarification of the mechanism of HFE associations in leukemia and cancer will have strong implications in public health. | 0.015645278 | 2005 | HFE | 6 | 26092913 | G | A |
rs1800566 | 22976839 | 5444 | PON1 | umls:C0023418 | BeFree | The NQO1 rs1800566 (C609T), PON1 rs854560 (L55M), and PON1 rs662 (Q192R) polymorphisms modified risk depending on leukemia subtype (decreased in AML, increased and decreased in ALL, respectively), age strata, and variant genotype combinations. | 0.000271442 | 2012 | NQO1 | 16 | 69711242 | G | A |
rs1800566 | 22976839 | 1728 | NQO1 | umls:C0023418 | BeFree | The NQO1 rs1800566 (C609T), PON1 rs854560 (L55M), and PON1 rs662 (Q192R) polymorphisms modified risk depending on leukemia subtype (decreased in AML, increased and decreased in ALL, respectively), age strata, and variant genotype combinations. | 0.023808397 | 2012 | NQO1 | 16 | 69711242 | G | A |
rs1800566 | 24571676 | 1728 | NQO1 | umls:C0023418 | BeFree | RAS mutations in early age leukaemia modulated by NQO1 rs1800566 (C609T) are associated with second-hand smoking exposures. | 0.023808397 | 2014 | NQO1 | 16 | 69711242 | G | A |
rs1801394 | 24261678 | 4552 | MTRR | umls:C0023418 | BeFree | Methionine synthase reductase A66G polymorphism and leukemia risk: evidence from published studies. | 0.007729856 | 2015 | MTRR;FASTKD3 | 5 | 7870860 | A | G |
rs1801394 | 24261678 | 4548 | MTR | umls:C0023418 | BeFree | The MTRR A66G (rs1801394) polymorphism is found to be associated with decreased enzyme affinity for MTR, the gene that encodes MS, and has been widely investigated for cancer risk, including leukemia. | 0.002638474 | 2015 | MTRR;FASTKD3 | 5 | 7870860 | A | G |
rs1805373 | 17651912 | 4968 | OGG1 | umls:C0023418 | BeFree | A novel R229Q OGG1 polymorphism results in a thermolabile enzyme that sensitizes KG-1 leukemia cells to DNA damaging agents. | 0.003267234 | 2007 | OGG1 | 3 | 9754824 | G | A |
rs2032582 | 24142546 | 5243 | ABCB1 | umls:C0023418 | BeFree | Association of MDR1 G2677T polymorphism and leukemia risk: evidence from a meta-analysis. | 0.054740296 | 2013 | ABCB1 | 7 | 87531302 | A | T,C |
rs2413739 | 22846425 | 11252 | PACSIN2 | umls:C0023418 | BeFree | The association of a PACSIN2 SNP (rs2413739) with TPMT activity was confirmed in patients and knock-down of PACSIN2 mRNA in human leukemia cells (NALM6) resulted in significantly lower TPMT activity. | 0.000271442 | 2012 | PACSIN2 | 22 | 43001030 | C | T |
rs2413739 | 22846425 | 7172 | TPMT | umls:C0023418 | BeFree | The association of a PACSIN2 SNP (rs2413739) with TPMT activity was confirmed in patients and knock-down of PACSIN2 mRNA in human leukemia cells (NALM6) resulted in significantly lower TPMT activity. | 0.020836349 | 2012 | PACSIN2 | 22 | 43001030 | C | T |
rs25487 | 23990457 | 7515 | XRCC1 | umls:C0023418 | BeFree | XRCC1 Arg399Gln variation and leukemia susceptibility: evidence from 2,647 cases and 5,518 controls. | 0.015916719 | 2013 | XRCC1 | 19 | 43551574 | T | C |
rs25487 | 25619474 | 7515 | XRCC1 | umls:C0023418 | BeFree | The current meta-analysis indicated that the Arg399Gln polymorphism in the XRCC1 gene might be a risk factor for hematological malignancies in Asians or for leukemia. | 0.015916719 | 2014 | XRCC1 | 19 | 43551574 | T | C |
rs28933375 | 15755897 | 5551 | PRF1 | umls:C0023418 | BeFree | In this study, we expressed wild-type and mutated perforin in rat basophil leukemia cells to study the effect on lytic function of the substitutions A91V and N252S (commonly considered to be neutral polymorphisms) and 22 perforin missense substitutions first identified in HLH patients. | 0.001900093 | 2005 | PRF1 | 10 | 70598966 | T | C |
rs35602083 | 16320249 | 2322 | FLT3 | umls:C0023418 | BeFree | Our data suggest that the FLT3 D324N variant might be associated with a predisposition to different subtypes of leukemia. | 0.093278617 | 2006 | FLT3 | 13 | 28049450 | C | T |
rs35947132 | 15755897 | 5551 | PRF1 | umls:C0023418 | BeFree | In this study, we expressed wild-type and mutated perforin in rat basophil leukemia cells to study the effect on lytic function of the substitutions A91V and N252S (commonly considered to be neutral polymorphisms) and 22 perforin missense substitutions first identified in HLH patients. | 0.001900093 | 2005 | PRF1 | 10 | 70600631 | G | A |
rs368647662 | 15967214 | 7296 | TXNRD1 | umls:C0023418 | BeFree | Further, at least two studies now show that the inactivating NAD(P)H:quinone acceptor oxidoreductase (NQO1) C609T polymorphism is positively associated with leukemias arising in the first 1-2 years of life and polymorphisms in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene have been associated with adult and childhood ALL. | 0.000271442 | 2005 | TXNRD1 | 12 | 104265777 | C | T |
rs368647662 | 15967214 | 4524 | MTHFR | umls:C0023418 | BeFree | Further, at least two studies now show that the inactivating NAD(P)H:quinone acceptor oxidoreductase (NQO1) C609T polymorphism is positively associated with leukemias arising in the first 1-2 years of life and polymorphisms in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene have been associated with adult and childhood ALL. | 0.047207275 | 2005 | TXNRD1 | 12 | 104265777 | C | T |
rs370216745 | 21073132 | 1728 | NQO1 | umls:C0023418 | BeFree | Our results suggest that increased risk of infant leukemia development in patients with NQO1 *1*3 polymorphism is partially dependent on the inhibition of p53 pathway, though further studies are needed to fully understand the pathological role of C465T variant in the development of childhood leukemia. | 0.023808397 | 2010 | TP53 | 17 | 7674949 | A | G |
rs370216745 | 21073132 | 7157 | TP53 | umls:C0023418 | BeFree | Our results suggest that increased risk of infant leukemia development in patients with NQO1 *1*3 polymorphism is partially dependent on the inhibition of p53 pathway, though further studies are needed to fully understand the pathological role of C465T variant in the development of childhood leukemia. | 0.057201797 | 2010 | TP53 | 17 | 7674949 | A | G |
rs3794845 | 20438785 | 4155 | MBP | umls:C0023418 | GAD | [Polymorphisms in innate immunity genes and risk of childhood leukemia.] | 0.002367032 | 2010 | MBP | 18 | 77002561 | G | C |
rs386493716 | 25619474 | 7515 | XRCC1 | umls:C0023418 | BeFree | The current meta-analysis indicated that the Arg399Gln polymorphism in the XRCC1 gene might be a risk factor for hematological malignancies in Asians or for leukemia. | 0.015916719 | 2014 | NA | NA | NA | NA | NA |
rs386493716 | 23990457 | 7515 | XRCC1 | umls:C0023418 | BeFree | XRCC1 Arg399Gln variation and leukemia susceptibility: evidence from 2,647 cases and 5,518 controls. | 0.015916719 | 2013 | NA | NA | NA | NA | NA |
rs386626619 | 21326037 | 4352 | MPL | umls:C0023418 | BeFree | Mutations in the thrombopoietin receptor gene (myeloproliferative leukemia, MPL) have been reported in patients with JAK2 V617F-negative chronic myeloproliferative disorders (MPDs). | 0.005167327 | 2011 | NA | NA | NA | NA | NA |
rs386626619 | 25479752 | 4297 | KMT2A | umls:C0023418 | BeFree | In mice, tamoxifen treatment blocked development of JAK2(V617F)-induced myeloproliferative neoplasm in vivo, induced apoptosis of human JAK2(V617F+) HSPCs in a xenograft model, and sensitized MLL-AF9(+) leukemias to chemotherapy. | 0.240150617 | 2014 | NA | NA | NA | NA | NA |
rs386626619 | 23432162 | 3717 | JAK2 | umls:C0023418 | BeFree | Continued research into how miRNAs impact JAK2(V617F) clonal expansion, differential haematopoiesis among different MPNs, disease progression and leukaemia transformation will lead to a better understanding of the development of these disorders, their clinical manifestations, and their treatment. | 0.144970109 | 2013 | NA | NA | NA | NA | NA |
rs386626619 | 19691103 | 3717 | JAK2 | umls:C0023418 | BeFree | JAK2 (V617F)-positive ET may evolve in few instances into JAK2-negative leukemia. | 0.144970109 | 2009 | NA | NA | NA | NA | NA |
rs386626619 | 21712540 | 3717 | JAK2 | umls:C0023418 | BeFree | Among the patients with myelofibrosis, those with ASXL1 lesions were not distinguished from their wild-type counterparts with regard to JAK2 V617F status, exposure to chemotherapy or evolution to leukemia. | 0.144970109 | 2011 | NA | NA | NA | NA | NA |
rs387906517 | 15194504 | 25 | ABL1 | umls:C0023418 | BeFree | The resistance to the tyrosine kinase inhibitor imatinib in BCR/ABL-positive leukemias is mostly associated with mutations in the kinase domain of BCR/ABL, which include the most prevalent mutations E255K and T315I. | 0.089268157 | 2004 | ABL1 | 9 | 130862919 | G | A |
rs387906553 | 12384420 | 1991 | ELANE | umls:C0023418 | BeFree | Collectively, these data suggest that expression of V72M NE is not sufficient to induce an SCN phenotype or leukemia in mice. | 0.001357209 | 2002 | ELANE | 19 | 853022 | G | A |
rs387906666 | 25939664 | 867 | CBL | umls:C0023418 | BeFree | The penetrance of the CBL Y371C mutation was 30% for JMML and 40% for all leukemia. | 0.000814326 | 2015 | CBL | 11 | 119278182 | A | G |
rs387907272 | 26230596 | 4615 | MYD88 | umls:C0023418 | BeFree | Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia. | 0.000271442 | 2015 | MYD88 | 3 | 38141150 | T | C |
rs397507444 | 16182363 | 4524 | MTHFR | umls:C0023418 | BeFree | Our investigation provides interesting data concerning the opposite effect of A1298C polymorphisms, particularly in the light of relatively scarce data regarding the MTHFR role in leukemia susceptibility in different populations. | 0.047207275 | 2006 | MTHFR | 1 | 11794407 | T | G |
rs662 | 22976839 | 1728 | NQO1 | umls:C0023418 | BeFree | The NQO1 rs1800566 (C609T), PON1 rs854560 (L55M), and PON1 rs662 (Q192R) polymorphisms modified risk depending on leukemia subtype (decreased in AML, increased and decreased in ALL, respectively), age strata, and variant genotype combinations. | 0.023808397 | 2012 | PON1 | 7 | 95308134 | T | C |
rs662 | 22976839 | 5444 | PON1 | umls:C0023418 | BeFree | The NQO1 rs1800566 (C609T), PON1 rs854560 (L55M), and PON1 rs662 (Q192R) polymorphisms modified risk depending on leukemia subtype (decreased in AML, increased and decreased in ALL, respectively), age strata, and variant genotype combinations. | 0.000271442 | 2012 | PON1 | 7 | 95308134 | T | C |
rs703817 | 20438785 | 6778 | STAT6 | umls:C0023418 | GAD | [Polymorphisms in innate immunity genes and risk of childhood leukemia.] | 0.002367032 | 2010 | STAT6 | 12 | 57096045 | C | T |
rs77375493 | 23432162 | 3717 | JAK2 | umls:C0023418 | BeFree | Continued research into how miRNAs impact JAK2(V617F) clonal expansion, differential haematopoiesis among different MPNs, disease progression and leukaemia transformation will lead to a better understanding of the development of these disorders, their clinical manifestations, and their treatment. | 0.144970109 | 2013 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
rs77375493 | 21712540 | 3717 | JAK2 | umls:C0023418 | BeFree | Among the patients with myelofibrosis, those with ASXL1 lesions were not distinguished from their wild-type counterparts with regard to JAK2 V617F status, exposure to chemotherapy or evolution to leukemia. | 0.144970109 | 2011 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
rs77375493 | 19691103 | 3717 | JAK2 | umls:C0023418 | BeFree | JAK2 (V617F)-positive ET may evolve in few instances into JAK2-negative leukemia. | 0.144970109 | 2009 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
rs77375493 | 21326037 | 4352 | MPL | umls:C0023418 | BeFree | Mutations in the thrombopoietin receptor gene (myeloproliferative leukemia, MPL) have been reported in patients with JAK2 V617F-negative chronic myeloproliferative disorders (MPDs). | 0.005167327 | 2011 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
rs77375493 | 25479752 | 4297 | KMT2A | umls:C0023418 | BeFree | In mice, tamoxifen treatment blocked development of JAK2(V617F)-induced myeloproliferative neoplasm in vivo, induced apoptosis of human JAK2(V617F+) HSPCs in a xenograft model, and sensitized MLL-AF9(+) leukemias to chemotherapy. | 0.240150617 | 2014 | JAK2;INSL6 | 9 | 5073770 | G | A,T |
rs854560 | 22976839 | 5444 | PON1 | umls:C0023418 | BeFree | The NQO1 rs1800566 (C609T), PON1 rs854560 (L55M), and PON1 rs662 (Q192R) polymorphisms modified risk depending on leukemia subtype (decreased in AML, increased and decreased in ALL, respectively), age strata, and variant genotype combinations. | 0.000271442 | 2012 | PON1 | 7 | 95316772 | A | C,G,N,T |
rs854560 | 22976839 | 1728 | NQO1 | umls:C0023418 | BeFree | The NQO1 rs1800566 (C609T), PON1 rs854560 (L55M), and PON1 rs662 (Q192R) polymorphisms modified risk depending on leukemia subtype (decreased in AML, increased and decreased in ALL, respectively), age strata, and variant genotype combinations. | 0.023808397 | 2012 | PON1 | 7 | 95316772 | A | C,G,N,T |
rs861539 | 24304418 | 7517 | XRCC3 | umls:C0023418 | BeFree | Association of XRCC3 Thr241Met polymorphism and leukemia risk: evidence from a meta-analysis. | 0.007915422 | 2015 | KLC1;XRCC3 | 14 | 103699416 | G | A |
rs861539 | 24197983 | 7517 | XRCC3 | umls:C0023418 | BeFree | Comprehensive assessment of the association between DNA repair gene XRCC3 Thr241Met polymorphism and leukemia risk. | 0.007915422 | 2013 | KLC1;XRCC3 | 14 | 103699416 | G | A |
rs874881 | 17216583 | 23569 | PADI4 | umls:C0023418 | BeFree | The functional haplotype of peptidylarginine deiminase IV (S55G, A82V and A112G) associated with susceptibility to rheumatoid arthritis dominates apoptosis of acute T leukemia Jurkat cells. | 0.002995792 | 2007 | PADI4 | 1 | 17334004 | G | C,T |
GWASdb Annotation(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Snp Trait(Total Genotypes:112) | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CHR | POS | SNPID | REF | ALT | ORI_SNPID | PMID | P_VALUE | P_VALUE_TEXT | OR/BETA | CI95_TEXT | GWAS_INITIAL_SAMPLE_SIZE | SUB_POPULATION | SUPER_POPULATION | GWAS_TRAIT | HPO_ID | HPO_TERM | DO_ID | DO_TERM | MESH_ID | MESH_TERM | EFO_ID | EFO_TERM | DOLITE_TERM | RISK_ALLELE | PUBLICATION_TYPE | AA | GENE_SYMBOL | TYPE | REFGENE |
1 | 20930035 | rs517483 | C | T | rs517483 | pha003091 | 2.69E-05 | phs000221 | phs000501 | 0.26 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
1 | 60876146 | rs7529292 | T | C | rs7529292 | pha003091 | 8.76E-05 | phs000221 | phs000501 | 0.24 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
1 | 65580328 | rs1572664 | C | A | rs1572664 | pha003091 | 2.25E-05 | phs000221 | phs000501 | 0.28 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
1 | 65580573 | rs11208589 | T | C | rs11208589 | pha003091 | 6.06E-05 | phs000221 | phs000501 | 0.28 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
1 | 77818143 | rs6672375 | A | G | rs6672375 | pha003091 | 4.20E-05 | phs000221 | phs000501 | 0.29 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
1 | 157811585 | rs2281870 | G | T | rs2281870 | pha003091 | 5.14E-05 | phs000221 | phs000501 | 0.43 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
1 | 198564497 | rs12144380 | T | C | rs12144380 | pha003091 | 7.75E-05 | phs000221 | phs000501 | 0.21 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
1 | 237420086 | rs918241 | C | A | rs918241 | pha003091 | 4.52E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
1 | 237433239 | rs4659491 | T | C | rs4659491 | pha003091 | 5.78E-06 | phs000221 | phs000501 | 0.22 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
2 | 34116688 | rs773820 | G | T | rs773820 | pha003091 | 7.33E-05 | phs000221 | phs000501 | 0.27 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
2 | 41996612 | rs4381822 | A | G | rs4381822 | pha003091 | 9.32E-05 | phs000221 | phs000501 | 0.19 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
2 | 52017764 | rs11686436 | C | T | rs11686436 | pha003091 | 1.06E-05 | phs000221 | phs000501 | 0.22 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
2 | 129981872 | rs1251207 | G | T | rs1251207 | pha003091 | 5.44E-05 | phs000221 | phs000501 | 0.24 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
2 | 190146586 | rs10207860 | C | T | rs10207860 | pha003091 | 5.50E-05 | phs000221 | phs000501 | 0.38 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
2 | 223758070 | rs795887 | C | T | rs795887 | pha003091 | 5.69E-05 | phs000221 | phs000501 | 0.03 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
2 | 223766830 | rs6722420 | A | G | rs6722420 | pha003091 | 7.81E-05 | phs000221 | phs000501 | 0.24 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
2 | 223808401 | rs10755042 | A | C | rs10755042 | pha003091 | 9.35E-05 | phs000221 | phs000501 | 0.24 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
2 | 240574731 | rs10165876 | G | A | rs10165876 | pha003091 | 3.62E-05 | phs000221 | phs000501 | 0.21 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
3 | 52825912 | rs7549 | C | A | rs7549 | pha003091 | 8.76E-06 | phs000221 | phs000501 | NA | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
3 | 55105390 | rs358070 | C | A | rs358070 | pha003091 | 6.88E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
3 | 128594995 | rs789214 | A | G | rs789214 | pha003091 | 9.59E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
3 | 171937014 | rs6445047 | T | C | rs6445047 | pha003091 | 3.30E-05 | phs000221 | phs000501 | 0.24 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
3 | 171943473 | rs7428410 | C | T | rs7428410 | pha003091 | 2.01E-05 | phs000221 | phs000501 | 0.25 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
3 | 171945349 | rs13073573 | C | T | rs13073573 | pha003091 | 2.83E-05 | phs000221 | phs000501 | 0.24 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
3 | 171951160 | rs4364195 | A | G | rs4364195 | pha003091 | 8.18E-05 | phs000221 | phs000501 | 0.23 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
4 | 7807834 | rs1106248 | T | C | rs1106248 | pha003091 | 7.67E-05 | phs000221 | phs000501 | 0.19 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
4 | 7831935 | rs6446628 | A | C | rs6446628 | pha003091 | 4.49E-06 | phs000221 | phs000501 | 0.24 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
4 | 25476612 | rs2875417 | G | A | rs2875417 | pha003091 | 7.58E-05 | phs000221 | phs000501 | 0.31 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
4 | 25531234 | rs6448367 | A | G | rs6448367 | pha003091 | 8.17E-05 | phs000221 | phs000501 | 0.32 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
4 | 25536386 | rs10018150 | A | G | rs10018150 | pha003091 | 5.00E-05 | phs000221 | phs000501 | 0.33 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
4 | 31335371 | rs10517227 | T | C | rs10517227 | pha003091 | 9.37E-05 | phs000221 | phs000501 | 0.22 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
4 | 40368848 | rs10021851 | G | A | rs10021851 | pha003091 | 2.88E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
4 | 60257454 | rs7681982 | T | C | rs7681982 | pha003091 | 1.08E-05 | phs000221 | phs000501 | 0.22 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
4 | 60283466 | rs1511404 | A | C | rs1511404 | pha003091 | 1.18E-05 | phs000221 | phs000501 | 0.22 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
4 | 60306500 | rs2048462 | T | C | rs2048462 | pha003091 | 9.57E-06 | phs000221 | phs000501 | 0.22 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
4 | 60314905 | rs6826593 | T | C | rs6826593 | pha003091 | 1.26E-05 | phs000221 | phs000501 | 0.21 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
4 | 60442490 | rs17290779 | T | C | rs17290779 | pha003091 | 9.82E-05 | phs000221 | phs000501 | 0.23 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
4 | 157104958 | rs12508572 | T | C | rs12508572 | pha003091 | 9.79E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
4 | 170232880 | rs13128807 | G | A | rs13128807 | pha003091 | 7.30E-05 | phs000221 | phs000501 | 0.21 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
5 | 11190339 | rs32275 | T | C | rs32275 | pha003091 | 3.26E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
5 | 101638381 | rs1982418 | G | A | rs1982418 | pha003091 | 6.94E-05 | phs000221 | phs000501 | 0.21 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
5 | 101669015 | rs12655961 | G | A | rs12655961 | pha003091 | 9.70E-06 | phs000221 | phs000501 | 0.23 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
5 | 101843759 | rs953280 | T | C | rs953280 | pha003091 | 3.45E-05 | phs000221 | phs000501 | 0.04 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
5 | 102003138 | rs2671569 | A | G | rs2671569 | pha003091 | 9.95E-05 | phs000221 | phs000501 | 0.19 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
5 | 176601031 | rs1546363 | C | T | rs1546363 | pha003091 | 3.51E-05 | phs000221 | phs000501 | 0.26 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
6 | 8273873 | rs591705 | G | A | rs591705 | pha003091 | 1.42E-05 | phs000221 | phs000501 | 0.23 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
6 | 8278455 | rs663716 | T | C | rs663716 | pha003091 | 1.58E-05 | phs000221 | phs000501 | 0.23 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
6 | 39174612 | rs10947788 | C | T | rs10947788 | pha003091 | 5.30E-05 | phs000221 | phs000501 | 0.21 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
6 | 45928400 | rs1555214 | C | T | rs1555214 | pha003091 | 1.32E-05 | phs000221 | phs000501 | 0.22 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
6 | 110250208 | rs9374140 | T | C | rs9374140 | pha003091 | 2.47E-05 | phs000221 | phs000501 | 0.23 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
6 | 145162225 | rs1111808 | A | G | rs1111808 | pha003091 | 1.88E-05 | phs000221 | phs000501 | 0.04 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
6 | 145162512 | rs1111807 | T | G | rs1111807 | pha003091 | 1.98E-05 | phs000221 | phs000501 | 0.34 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
6 | 145169607 | rs6903007 | T | C | rs6903007 | pha003091 | 8.65E-06 | phs000221 | phs000501 | 0.35 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
6 | 145184504 | rs4321838 | A | C | rs4321838 | pha003091 | 7.15E-06 | phs000221 | phs000501 | 0.34 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
7 | 73724962 | rs229877 | C | T | rs229877 | pha003091 | 8.18E-05 | phs000221 | phs000501 | 0.22 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
7 | 73760704 | rs523434 | G | A | rs523434 | pha003091 | 1.42E-05 | phs000221 | phs000501 | 0.24 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
7 | 90840353 | rs11970859 | G | A | rs11970859 | pha003091 | 1.70E-05 | phs000221 | phs000501 | 0.38 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
7 | 134471211 | rs6467557 | T | G | rs6467557 | pha003091 | 7.44E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
7 | 138380477 | rs6944016 | G | A | rs6944016 | pha003091 | 1.99E-05 | phs000221 | phs000501 | 0.43 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
8 | 76028740 | rs1378615 | C | T | rs1378615 | pha003091 | 4.43E-05 | phs000221 | phs000501 | 0.25 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
8 | 101268237 | rs1660350 | G | A | rs1660350 | pha003091 | 1.82E-05 | phs000221 | phs000501 | 0.21 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
8 | 125571747 | rs6470250 | T | C | rs6470250 | pha003091 | 9.72E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
8 | 139975998 | rs6577977 | C | A | rs6577977 | pha003091 | 6.22E-05 | phs000221 | phs000501 | 0.23 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
9 | 10311825 | rs635858 | C | T | rs635858 | pha003091 | 1.41E-05 | phs000221 | phs000501 | 0.27 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
9 | 10314941 | rs680760 | T | C | rs680760 | pha003091 | 9.49E-06 | phs000221 | phs000501 | 0.27 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
9 | 10336364 | rs10114902 | T | C | rs10114902 | pha003091 | 7.59E-05 | phs000221 | phs000501 | 0.23 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
9 | 72429750 | rs7863087 | T | C | rs7863087 | pha003091 | 4.22E-05 | phs000221 | phs000501 | 0.39 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
9 | 77535027 | rs12379179 | T | C | rs12379179 | pha003091 | 3.90E-05 | phs000221 | phs000501 | 0.29 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
9 | 127710312 | rs13299805 | T | C | rs13299805 | pha003091 | 3.73E-05 | phs000221 | phs000501 | 0.43 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
10 | 1923792 | rs7073281 | G | T | rs7073281 | pha003091 | 5.51E-05 | phs000221 | phs000501 | 0.28 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
10 | 72424452 | rs17528058 | C | T | rs17528058 | pha003091 | 5.97E-05 | phs000221 | phs000501 | 0.22 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
10 | 97269933 | rs12776562 | C | A | rs12776562 | pha003091 | 7.98E-06 | phs000221 | phs000501 | 0.23 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
10 | 97284081 | rs1326934 | C | T | rs1326934 | pha003091 | 6.21E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
10 | 97289992 | rs11188346 | G | A | rs11188346 | pha003091 | 2.83E-05 | phs000221 | phs000501 | 0.23 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
10 | 97294813 | rs10882611 | G | A | rs10882611 | pha003091 | 1.31E-05 | phs000221 | phs000501 | 0.24 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
10 | 117844044 | rs7087152 | C | T | rs7087152 | pha003091 | 6.09E-05 | phs000221 | phs000501 | 0.25 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
11 | 11505004 | rs12293824 | G | A | rs12293824 | pha003091 | 6.67E-05 | phs000221 | phs000501 | 0.34 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
11 | 21436232 | rs11026076 | T | C | rs11026076 | pha003091 | 2.09E-06 | phs000221 | phs000501 | 0.23 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
11 | 21437692 | rs7943922 | T | G | rs7943922 | pha003091 | 3.07E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
11 | 21522529 | rs10219188 | T | G | rs10219188 | pha003091 | 3.85E-05 | phs000221 | phs000501 | 0.19 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
11 | 44363600 | rs4755813 | C | T | rs4755813 | pha003091 | 5.07E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
11 | 123038840 | rs10790558 | A | G | rs57232670 | pha003091 | 9.15E-05 | phs000221 | phs000501 | 0.19 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
12 | 22976813 | rs12581238 | T | C | rs12581238 | pha003091 | 3.85E-05 | phs000221 | phs000501 | 0.35 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
12 | 50335086 | rs296742 | T | C | rs296742 | pha003091 | 8.92E-05 | phs000221 | phs000501 | 0.24 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
12 | 99135638 | rs4762507 | C | T | rs4762507 | pha003091 | 1.27E-05 | phs000221 | phs000501 | 0.27 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
12 | 115206320 | rs1566643 | A | G | rs1566643 | pha003091 | 4.16E-05 | phs000221 | phs000501 | 0.19 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
12 | 115453154 | rs10850428 | C | T | rs10850428 | pha003091 | 8.19E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
13 | 23827815 | rs7995077 | G | A | rs7995077 | pha003091 | 6.14E-05 | phs000221 | phs000501 | 0.19 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
13 | 23855056 | rs11617228 | T | C | rs11617228 | pha003091 | 5.42E-05 | phs000221 | phs000501 | 0.22 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
13 | 23864250 | rs1887756 | G | T | rs1887756 | pha003091 | 1.95E-05 | phs000221 | phs000501 | 0.23 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
13 | 84214404 | rs7322996 | T | C | rs7322996 | pha003091 | 5.24E-05 | phs000221 | phs000501 | 0.24 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
13 | 94490519 | rs1330458 | C | T | rs1330458 | pha003091 | 7.94E-05 | phs000221 | phs000501 | 0.37 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
14 | 58452939 | rs808208 | G | A | rs808208 | pha003091 | 8.08E-05 | phs000221 | phs000501 | 0.19 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
14 | 59180300 | rs8022761 | T | C | rs8022761 | pha003091 | 3.35E-05 | phs000221 | phs000501 | 0.26 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
14 | 65336050 | rs2828 | T | G | rs2828 | pha003091 | 9.98E-05 | phs000221 | phs000501 | 0.21 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
15 | 78439120 | rs2028548 | C | T | rs2028548 | pha003091 | 5.75E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
16 | 7420486 | rs7206595 | G | A | rs7206595 | pha003091 | 4.26E-05 | phs000221 | phs000501 | 0.19 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
16 | 7433110 | rs4627375 | A | G | rs4627375 | pha003091 | 6.66E-05 | phs000221 | phs000501 | 0.19 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
16 | 24462555 | rs9930580 | T | C | rs9930580 | pha003091 | 1.30E-05 | phs000221 | phs000501 | 0.45 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
16 | 64221018 | rs9931309 | C | A | rs9931309 | pha003091 | 1.50E-05 | phs000221 | phs000501 | 0.26 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
17 | 8595094 | rs7213402 | C | T | rs7213402 | pha003091 | 2.09E-05 | phs000221 | phs000501 | 0.21 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
17 | 26106675 | rs4795067 | A | G | rs4795067 | pha003091 | 9.94E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
17 | 32159519 | rs2881782 | A | C | rs2881782 | pha003091 | 9.96E-05 | phs000221 | phs000501 | 0.19 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
17 | 63099682 | rs1808918 | C | T | rs1808918 | pha003091 | 3.35E-05 | phs000221 | phs000501 | 0.2 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
18 | 4025719 | rs1442385 | G | A | rs1442385 | pha003091 | 2.91E-05 | phs000221 | phs000501 | 0.23 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
18 | 11759432 | rs9947295 | C | T | rs9947295 | pha003091 | 6.25E-05 | phs000221 | phs000501 | 0.32 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
19 | 49361255 | rs17206700 | T | C | rs17206700 | pha003091 | 1.44E-05 | phs000221 | phs000501 | 0.27 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
19 | 49362992 | rs17272673 | C | A | rs17272673 | pha003091 | 1.55E-05 | phs000221 | phs000501 | 0.27 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
20 | 17479730 | rs6111549 | T | C | rs6111549 | pha003091 | 2.20E-05 | phs000221 | phs000501 | 0.21 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
21 | 16848564 | rs2823295 | T | C | rs2823295 | pha003091 | 1.42E-05 | phs000221 | phs000501 | 0.27 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
21 | 31050817 | rs363512 | G | A | rs363512 | pha003091 | 2.15E-05 | phs000221 | phs000501 | 0.39 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
22 | 48178105 | rs9627141 | A | G | rs9627141 | pha003091 | 6.51E-05 | phs000221 | phs000501 | 0.31 | NA | NA | ALL(0) | ALL(0) | Leukocyte Counts | HPOID:0001909 | Leukemia | DOID:1240 | DOID:0060058 | DOID:1287 | leukemia | lymphoma | cardiovascular system disease | NA | NA | NA | NA | Lymphoma | Leukemia |
Mapped by lexical matching(Total Items:0) |
---|
(Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
---|
(Waiting for update.) |
Chemical(Total Drugs:32) | |||||||||
---|---|---|---|---|---|---|---|---|---|
CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
C0023418 | amlodipine | D017311 | 88150-42-9 | leukemia | MESH:D007938 | therapeutic | 16684125 | ||
C0023418 | amsacrine | D000677 | - | leukemia | MESH:D007938 | therapeutic | 3681383 | ||
C0023418 | arsenic trioxide | C006632 | 1327-53-3 | leukemia | MESH:D007938 | therapeutic | 15070760 | ||
C0023418 | azacitidine | D001374 | 320-67-2 | leukemia | MESH:D007938 | marker/mechanism | 2408741 | ||
C0023418 | azacitidine | D001374 | 320-67-2 | leukemia | MESH:D007938 | therapeutic | 19148494 | ||
C0023418 | bortezomib | D000069286 | - | leukemia | MESH:D007938 | therapeutic | 15039284 | ||
C0023418 | carmustine | D002330 | 154-93-8 | leukemia | MESH:D007938 | therapeutic | 11960597 | ||
C0023418 | chlorambucil | D002699 | 305-03-3 | leukemia | MESH:D007938 | therapeutic | 118440 | ||
C0023418 | chloramphenicol | D002701 | 56-75-7 | leukemia | MESH:D007938 | marker/mechanism | 1211407 | ||
C0023418 | chloramphenicol | D002701 | 56-75-7 | leukemia | MESH:D007938 | therapeutic | 8834551 | ||
C0023418 | cyclophosphamide | D003520 | 50-18-0 | leukemia | MESH:D007938 | marker/mechanism | 572348 | ||
C0023418 | cyclophosphamide | D003520 | 50-18-0 | leukemia | MESH:D007938 | therapeutic | 10602166 | ||
C0023418 | dasatinib | D000069439 | - | leukemia | MESH:D007938 | therapeutic | 28243904 | ||
C0023418 | decitabine | C014347 | 2353-33-5 | leukemia | MESH:D007938 | therapeutic | 18980019 | ||
C0023418 | cisplatin | D002945 | 15663-27-1 | leukemia | MESH:D007938 | marker/mechanism | 24798381 | ||
C0023418 | calcitriol | D002117 | 32222-06-3 | leukemia | MESH:D007938 | therapeutic | 10470102 | ||
C0023418 | hydroxyurea | D006918 | 127-07-1 | leukemia | MESH:D007938 | marker/mechanism | 11317962 | ||
C0023418 | hydroxyurea | D006918 | 127-07-1 | leukemia | MESH:D007938 | therapeutic | 17686055 | ||
C0023418 | ifosfamide | D007069 | 3778-73-2 | leukemia | MESH:D007938 | marker/mechanism | 7596151 | ||
C0023418 | imatinib mesylate | D000068877 | - | leukemia | MESH:D007938 | therapeutic | 24240679 | ||
C0023418 | lindane | D001556 | 58-89-9 | leukemia | MESH:D007938 | marker/mechanism | 17096337 | ||
C0023418 | methotrexate | D008727 | 1959/5/2 | leukemia | MESH:D007938 | therapeutic | 10458822 | ||
C0023418 | mitoxantrone | D008942 | 65271-80-9 | leukemia | MESH:D007938 | marker/mechanism | 15623667 | ||
C0023418 | mitoxantrone | D008942 | 65271-80-9 | leukemia | MESH:D007938 | therapeutic | 3481363 | ||
C0023418 | nelfinavir | D019888 | 159989-64-7 | leukemia | MESH:D007938 | therapeutic | 20105315 | ||
C0023418 | paclitaxel | D017239 | - | leukemia | MESH:D007938 | therapeutic | 7904060 | ||
C0023418 | paricalcitol | C084656 | - | leukemia | MESH:D007938 | therapeutic | 12618899 | ||
C0023418 | sorafenib | C471405 | - | leukemia | MESH:D007938 | therapeutic | 17205056 | ||
C0023418 | temozolomide | C047246 | 85622-93-1 | leukemia | MESH:D007938 | therapeutic | 15360003 | ||
C0023418 | tretinoin | D014212 | 302-79-4 | leukemia | MESH:D007938 | therapeutic | 17143497 | ||
C0023418 | vincristine | D014750 | - | leukemia | MESH:D007938 | therapeutic | 3875694 | ||
C0023418 | vindesine | D014751 | 53643-48-4 | leukemia | MESH:D007938 | therapeutic | 6268296 |
FDA approved drug and dosage information(Total Drugs:10) | ||||||||
---|---|---|---|---|---|---|---|---|
DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
MESH:D007938 | calcijex | calcitriol | 0.001MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | INJECTABLE;INJECTION | Discontinued | None | Yes | No |
MESH:D007938 | temodar | temozolomide | 5MG | CAPSULE;ORAL | Prescription | AB | Yes | No |
MESH:D007938 | temodar | temozolomide | 100MG/VIAL | POWDER;INTRAVENOUS | Prescription | None | Yes | Yes |
MESH:D007938 | zemplar | paricalcitol | 0.005MG/ML (0.005MG/ML) | SOLUTION;INTRAVENOUS | Prescription | AP | Yes | Yes |
MESH:D007938 | zemplar | paricalcitol | 1MCG | CAPSULE;ORAL | Prescription | AB | No | No |
MESH:D007938 | zemplar | paricalcitol | 0.005MG/ML (0.005MG/ML) | SOLUTION;INTRAVENOUS | Prescription | AP | Yes | Yes |
MESH:D007938 | zemplar | paricalcitol | 1MCG | CAPSULE;ORAL | Prescription | AB | No | No |
MESH:D007938 | gleevec | imatinib mesylate | EQ 50MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | CAPSULE;ORAL | Discontinued | None | Yes | No |
MESH:D007938 | gleevec | imatinib mesylate | EQ 100MG BASE | TABLET;ORAL | Prescription | AB | Yes | No |
MESH:D007938 | velcade | bortezomib | 3.5MG/VIAL | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | Prescription | None | Yes | Yes |
FDA labeling changes(Total Drugs:10) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
MESH:D007938 | 11/16/2001 | calcijex | calcitriol | Management of hypocalcemia in patients undergoing chronic renal dialysis | The safety and effectiveness of calcitriol was examined in a double-blind placebo-controlled trial of 35 pediatric patients (13-18 years of age) with end-stage renal disease and on dialysis. The primary efficacy endpoint favored the calcitriol-treated versus the placebo-treated patients Transient hypercalcemia was seen in 1 of 16 calcitriol-treated patients; 6 of 16 (38%) calcitriol-treated patients and 2 of 19 (11%) placebo-treated patients had Ca x P >75 | Labeling | B | - | - | - | Abbott | 02/16/2001 | FALSE' |
MESH:D007938 | 11/3/2003 | temodar | temozolomide | Recurrent CNS tumors | Temozolomide effectiveness in children has not been demonstrated New data from 2 open-label Phase 2 studies in pediatric patients 3-18 years of age. In one study there were 29 patients with recurrent brain stem glioma and 34 patients with recurrent high grade astrocyoma. In a second study there were 122 patients enrolled with various types of tumors; 113 CNS tumors and 9 non-CNS tumors. The temozolomide toxicity profile in children is similar to adults | Labeling | B | - | - | - | Schering | 11/20/2002 | FALSE' |
MESH:D007938 | 11/3/2003 | temodar | temozolomide | Recurrent CNS tumors | Temozolomide effectiveness in children has not been demonstrated New data from 2 open-label Phase 2 studies in pediatric patients 3-18 years of age. In one study there were 29 patients with recurrent brain stem glioma and 34 patients with recurrent high grade astrocyoma. In a second study there were 122 patients enrolled with various types of tumors; 113 CNS tumors and 9 non-CNS tumors. The temozolomide toxicity profile in children is similar to adults | Labeling | B | - | - | - | Schering | 11/20/2002 | FALSE' |
MESH:D007938 | 03/31/2004 | zemplar | paricalcitol | Secondary hyperparathyroidism associated with end stage renal disease | Safety and effectiveness were examined in a 12 week randomized, double-blind, placebo-controlled study of 29 pediatric patients aged 5-19 years old with end stage renal disease on hemodialysis; information Primary efficacy analysis revealed 9 of 15 patients in Zemplar group had 2 consecutive 30 % decreases from baseline intact PTH compared with 3 of 14 patients in placebo group No patients in either group developed hypercalcemia (defined as at least one calcium value >11.2 mg/dL) during study | Labeling | B | - | - | - | Abbott | 8/12/2003 | FALSE' |
MESH:D007938 | 03/31/2004 | zemplar | paricalcitol | Secondary hyperparathyroidism associated with end stage renal disease | Safety and effectiveness were examined in a 12 week randomized, double-blind, placebo-controlled study of 29 pediatric patients aged 5-19 years old with end stage renal disease on hemodialysis; information Primary efficacy analysis revealed 9 of 15 patients in Zemplar group had 2 consecutive 30 % decreases from baseline intact PTH compared with 3 of 14 patients in placebo group No patients in either group developed hypercalcemia (defined as at least one calcium value >11.2 mg/dL) during study | Labeling | B | - | - | - | Abbott | 8/12/2003 | FALSE' |
MESH:D007938 | 10/18/2016 | zemplar | paricalcitol | Secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3, 4 and 5 in pediatric patients 10 to 16 years | Safety and effectiveness have been established in pediatric patients 10 to 16 years of age. Use in this age group is supported by evidence from adequate and well controlled studies in adults with CKD, a 12-week double-blind placebo-controlled randomized multicenter study in 36 pediatric patients 10 to 16 years of age with CKD Stages 3 and 4, and safety data from a 12-week open-label single-arm multicenter study in 13 pediatric patients 10 to 16 years of age with CKD Stage 5 receiving peritoneal dialysis or hemodialysis. Safety and effectiveness in pediatric patients under the age of 10 years have not been established. Adverse reactions were similar to those reported in adults. Information on dosing, pharmacokinetic parameters, and clinical trial. Postmarketing study | - | - | P | - | - | AbbVie Inc. | - | FALSE |
MESH:D007938 | 10/18/2016 | zemplar | paricalcitol | Secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3, 4 and 5 in pediatric patients 10 to 16 years | Safety and effectiveness have been established in pediatric patients 10 to 16 years of age. Use in this age group is supported by evidence from adequate and well controlled studies in adults with CKD, a 12-week double-blind placebo-controlled randomized multicenter study in 36 pediatric patients 10 to 16 years of age with CKD Stages 3 and 4, and safety data from a 12-week open-label single-arm multicenter study in 13 pediatric patients 10 to 16 years of age with CKD Stage 5 receiving peritoneal dialysis or hemodialysis. Safety and effectiveness in pediatric patients under the age of 10 years have not been established. Adverse reactions were similar to those reported in adults. Information on dosing, pharmacokinetic parameters, and clinical trial. Postmarketing study | - | - | P | - | - | AbbVie Inc. | - | FALSE |
MESH:D007938 | 09/27/2006 | gleevec | imatinib mesylate | Treatment of newly diagnosed pediatric patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase | Extended age range for the treatment of newly diagnosed CML down to pediatric patients There are no data in children < 2 years of age Follow-up in children with newly diagnosed Ph+ chronic phase CML is limited Information on hematologic toxicities, AE profile, clinical studies and dosing guidelines new for newly diagnosed pediatric patients | Labeling | - | - | B, P | - | Novartis | 9/6/2006 | FALSE' |
MESH:D007938 | 09/27/2006 | gleevec | imatinib mesylate | Treatment of newly diagnosed pediatric patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase | Extended age range for the treatment of newly diagnosed CML down to pediatric patients There are no data in children < 2 years of age Follow-up in children with newly diagnosed Ph+ chronic phase CML is limited Information on hematologic toxicities, AE profile, clinical studies and dosing guidelines new for newly diagnosed pediatric patients | Labeling | - | - | B, P | - | Novartis | 9/6/2006 | FALSE' |
MESH:D007938 | 09/14/2015 | velcade | bortezomib | Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) | Effectiveness in pediatric patients with relapsed pre-B ALL has not been established. The activity and safety of Velcade in combination with intensive reinduction chemotherapy was evaluated in pediatric and young adult patients with lymphoid malignancies. There were 140 patients with ALL or LL enrolled and evaluated for safety. No new safety concerns were observed | Labeling | B | - | - | - | Millennium Pharmaceuticals, Inc. | - | FALSE |